PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Iβ/SET

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4578-4586

  Anazawa, Yoshio ^a   Nakagawa, Hidewaki ^a   Furihara, Mutsuo ^b   Ashida, Shingo ^a,b   Tamura, Kenji ^a,b   Yoshioka, Hiroki ^a   Shuin, Taro ^b   Fujioka, Tomoaki ^c   Katagiri, Toyomasa ^a   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN ANTIBODY; PROTEIN PCOTH; PROTEIN TAF1BETA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ASSAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN PHOSPHORYLATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; COLLAGEN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 21144434780     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4564     Document Type: Article

References (31)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
2. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001;23:3-13.
3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
4. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-9.
5. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002;2:113-6.
6. Ashida S, Nakagawa H, Katagiri T, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004;64:5963-72.
7. Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the β-catenin/T-cell factor complex. Cancer Res 2003;63:6116-20.
8. Ferrell JE Jr, Martin GS. Thrombin stimulates the activities of multiple previously unidentified protein kinases in platelets. J Biol Chem 1989;264:20723-9.
9. Aronica SM, Gingras AC, Sonenberg N, Cooper S, Hague N, Broxmeyer HE. Macrophage inflammatory protein-1α and interferon-inducible protein 10 inhibit synergistically induced growth factor stimulation of MAP kinase activity and suppress phosphorylation of eukaryotic initiation factor 4E and 4E binding protein 1. Blood 1997;89:3582-95.
10. Aftab DT, Kwan J, Martin GS. Ras-independent transformation by v-Src. Proc Natl Acad Sci U S A 1997;94:3028-33.
11. Miyamoto E, Kakiuchi S, Kakimoto Y. In vitro and in vivo phosphorylation of myelin basic protein by cerebral protein kinase. Nature 1974;249:150-1.
12. Ulmer JB, Edwards AM, McMorris FA, Braun PE. Cyclic AMP decreases the phosphorylation state of myelin basic proteins in rat brain cell cultures. J Biol Chem 1987;262:1748-55.
13. +-dependent protein kinase from heart. II. Substrate specificity and inhibition by various agents. J Biol Chem 1982;257:8489-95.
14. Kishimoto A, Nishiyama K, Nakanishi H, et al. Studies on the phosphorylation of myelin basic protein by protein kinase C and adenosine 3′:5′-monophosphate-dependent protein kinase. J Biol Chem 1985;260:12492-9.
15. Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000;97:9390-5.
16. Zhou G, Li H, DeCamp D, et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002;1:117-24.
17. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
18. Sudarsanam P, Cao Y, Wu L, Laurent BC, Winston F. The nucleosome remodeling complex, Snf/Swi, is required for the maintenance of transcription in vivo and is partially redundant with the histone acetyltransferase, Gcn5. EMBO J 1999;18:3101-6.
19. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
20. Dedhar S, Rennie PS, Shago M, et al. Inhibition of nuclear hormone receptor activity by calreticulin. Nature 1994;367:480-3.
21. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol Cell Biol 1992;12:3346-55.
22. Li M, Makkinje A. Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996;271:11059-62.
23. Saito S, Miyaji-Yamaguchi M, Shimoyama T, Nagata K. Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun 1999;259:471-5.
24. Beresford PJ, Zhang D, Oh DY, et al. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem 2001;276:43285-93.
25. Fan Z, Beresford PJ, Zhang D, et al. Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol 2003;4:145-53.
26. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001;104:119-30.
27. Cervoni N, Detich N, Seo SB. Chakravarti D, Szyf M. The oncoprotein Set/TAF-1β, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem 2002;277:25026-31.
28. Estanyol JM, Jaumot M, Casanovas O, Rodriguez-Vilarrupla A, Agell N, Bachs O. The protein SET regulates the inhibitory effect of p21(Cip1) on cyclin E-cyclin-dependent kinase 2 activity. J Biol Chem 1999;274:33161-5.
29. 2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem 2003;278:1158-64.
30. Adachi Y, Pavlakis GN, Copeland TD. Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia. FEBS Lett 1994;340:231-5.
31. Nagata K, Saito S, Okuwaki M, et al. Cellular localization and expression of template-activating factor 1 in different cell types. Exp Cell Res 1998;240:274-81.